Iconovo [AB:PUBL]
PUBL]

According to a WHO report, each year nearly 262 million people are affected by asthma leading to an alarming number of deaths. While asthma is notably the most chronic respiratory ailment, several pulmonary diseases around the world are emerging as a global health concern. Apart from damaging the lungs and related respiratory arteries, medications of these diseases lead to increased number of cancers and other cardiac illnesses. While inhaler has been the best rescue medicine owing to its faster reach to affected areas and helping in systemic circulation, the regulatory complications often deter the easy accessibility of these products into the market.

This is precisely where Iconovo is bringing a difference. Based in Sweden, the company is capitalising on the relaxed compliance scenarios by bringing forth ready-to-use inhalation products such as inhaler devices and dry powder formulations. With an ingrained experience in both pharmaceutical and engineering fields, Iconovo draws insights from both the worlds to formulate solutions that rigorously meet the ISO 13485 standards and are require shorter time frames to be manufactured.

Iconovo offers a full range of ready-to-use inhalation devices that can be customised with customer’s substance. Under its hood, the company has four proprietary inhaler platforms that can be tailored with inhalation powder and made customer-specific in its applications. ICOres, its flagship product, is a flexible multi-dose dry powder inhaler comes with two separate reservoirs that allows for simultaneous inhalation of two different formulations. The product can deliver up to 180 doses of mono or combination therapies, either carrier-based formulations or active pharmaceutical ingredient (API) mixed with it. In addition, ICOres also comprises of a dose counter and an inhalation feedback feature, making it easier for users to receive and keep track of the doses.

Iconovo is a company with high ambitions. Now that we have increased the number of innovative projects in our pipeline in a short period of time and are getting closer and closer to launch, we think it is important to communicate financial goals

The uniquely designed capsule-based ICOcap is a grip friendly solution that ensures ease of use. Besides, it encompasses both in vitro and in vivo designs that can be further customised for special needs. A single dose disposable dry powder inhaler, ICOpre is extremely affordable and is pre-metered and is build for combination products. The product comes in both spray-dried and carried-based formulations and needs only three steps to function–open, inhale, and close. Also, ICOone contains two times 30 individually sealed doses for a month’s supply and even has a dose counter to check for remnants. Rounding off its product suite is ICOone that is a single disposable inhaler designed for simple, discreet, and cost-effective use. Owing to its user intuitiveness, the product acts as the perfect replacement for injections, thereby putting a rest for the need of any refrigeration and risk of syringes with contaminated blood.

With innovation at its core, Iconovo focuses on the part of the value chain where it can add significant value – the development of the inhalation product. As a customer-first company, it relies on its customers to bring its expertise in performing clinical trials, manufacturing, registration, and sales. Since its inception in 2013, Iconovo has been steering ahead of its competition curve and shows no sign of slowing down. In fact, the company plans to exhibit aggressive growth rate in the next five years. “Iconovo is a company with high ambitions. Now that we have increased the number of innovative projects in our pipeline in a short period of time and are getting closer and closer to launch, we think it is important to communicate financial goals,” concludes Johan Wäborg, CEO, Iconovo.